213 related articles for article (PubMed ID: 22907734)
1. Novel agents in acute myeloid leukemia.
Ungewickell A; Medeiros BC
Int J Hematol; 2012 Aug; 96(2):178-85. PubMed ID: 22907734
[TBL] [Abstract][Full Text] [Related]
2. Dose escalation of lenalidomide in relapsed or refractory acute leukemias.
Blum W; Klisovic RB; Becker H; Yang X; Rozewski DM; Phelps MA; Garzon R; Walker A; Chandler JC; Whitman SP; Curfman J; Liu S; Schaaf L; Mickle J; Kefauver C; Devine SM; Grever MR; Marcucci G; Byrd JC
J Clin Oncol; 2010 Nov; 28(33):4919-25. PubMed ID: 20956622
[TBL] [Abstract][Full Text] [Related]
3. Single-agent lenalidomide induces complete remission of acute myeloid leukemia in patients with isolated trisomy 13.
Fehniger TA; Byrd JC; Marcucci G; Abboud CN; Kefauver C; Payton JE; Vij R; Blum W
Blood; 2009 Jan; 113(5):1002-5. PubMed ID: 18824593
[TBL] [Abstract][Full Text] [Related]
4. Selective Inhibitors of Histone Deacetylases 1 and 2 Synergize with Azacitidine in Acute Myeloid Leukemia.
Min C; Moore N; Shearstone JR; Quayle SN; Huang P; van Duzer JH; Jarpe MB; Jones SS; Yang M
PLoS One; 2017; 12(1):e0169128. PubMed ID: 28060870
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors.
Xu QY; Yu L
Chin Med J (Engl); 2020 Mar; 133(6):699-715. PubMed ID: 32044818
[TBL] [Abstract][Full Text] [Related]
6. Molecularly targeted therapy in acute myeloid leukemia.
Gill H; Leung AY; Kwong YL
Future Oncol; 2016 Mar; 12(6):827-38. PubMed ID: 26828965
[TBL] [Abstract][Full Text] [Related]
7. Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.
Stahl M; Gore SD; Vey N; Prebet T
Expert Opin Investig Drugs; 2016; 25(3):307-17. PubMed ID: 26807602
[TBL] [Abstract][Full Text] [Related]
8. The role of decitabine for the treatment of acute myeloid leukemia.
Ganetsky A
Ann Pharmacother; 2012 Nov; 46(11):1511-7. PubMed ID: 23115225
[TBL] [Abstract][Full Text] [Related]
9. Combination therapy with DNA methyltransferase inhibitors in hematologic malignancies.
Gore SD
Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S30-5. PubMed ID: 16341238
[TBL] [Abstract][Full Text] [Related]
10. Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML).
Braun T; Gardin C
Expert Opin Investig Drugs; 2017 Jul; 26(7):803-811. PubMed ID: 28541716
[TBL] [Abstract][Full Text] [Related]
11. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
[TBL] [Abstract][Full Text] [Related]
12. A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia.
Fehniger TA; Uy GL; Trinkaus K; Nelson AD; Demland J; Abboud CN; Cashen AF; Stockerl-Goldstein KE; Westervelt P; DiPersio JF; Vij R
Blood; 2011 Feb; 117(6):1828-33. PubMed ID: 21051557
[TBL] [Abstract][Full Text] [Related]
13. New strategies for relapsed acute myeloid leukemia: fertile ground for translational research.
Dinner SN; Giles FJ; Altman JK
Curr Opin Hematol; 2014 Mar; 21(2):79-86. PubMed ID: 24419335
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic therapies in acute myeloid leukemia: where to from here?
Fennell KA; Bell CC; Dawson MA
Blood; 2019 Nov; 134(22):1891-1901. PubMed ID: 31697822
[TBL] [Abstract][Full Text] [Related]
15. Heat shock protein 90 inhibition is cytotoxic to primary AML cells expressing mutant FLT3 and results in altered downstream signalling.
Al Shaer L; Walsby E; Gilkes A; Tonks A; Walsh V; Mills K; Burnett A; Rowntree C
Br J Haematol; 2008 May; 141(4):483-93. PubMed ID: 18373709
[TBL] [Abstract][Full Text] [Related]
16. P-glycoprotein and breast cancer resistance protein in acute myeloid leukaemia cells treated with the aurora-B kinase inhibitor barasertib-hQPA.
Grundy M; Seedhouse C; Russell NH; Pallis M
BMC Cancer; 2011 Jun; 11():254. PubMed ID: 21679421
[TBL] [Abstract][Full Text] [Related]
17. DNA methyltransferase inhibitors in acute myeloid leukemia: discovery, design and first therapeutic experiences.
Thomas X
Expert Opin Drug Discov; 2012 Nov; 7(11):1039-51. PubMed ID: 22950862
[TBL] [Abstract][Full Text] [Related]
18. Heat shock protein 90 - a potential target in the treatment of human acute myelogenous leukemia.
Reikvam H; Ersvaer E; Bruserud O
Curr Cancer Drug Targets; 2009 Sep; 9(6):761-76. PubMed ID: 19754360
[TBL] [Abstract][Full Text] [Related]
19. Targeting of polo-like kinases and their cross talk with Aurora kinases--possible therapeutic strategies in human acute myeloid leukemia?
Tsykunova G; Reikvam H; Ahmed AB; Nepstad I; Gjertsen BT; Bruserud Ø
Expert Opin Investig Drugs; 2012 May; 21(5):587-603. PubMed ID: 22424119
[TBL] [Abstract][Full Text] [Related]
20. The combination of FLT3 and DNA methyltransferase inhibition is synergistically cytotoxic to FLT3/ITD acute myeloid leukemia cells.
Chang E; Ganguly S; Rajkhowa T; Gocke CD; Levis M; Konig H
Leukemia; 2016 May; 30(5):1025-32. PubMed ID: 26686245
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
